Treatment of Ocular Sarcoidosis. Study of 65 Patients From a Series of 342 From a University Hospital in Northern Spain

Ocular involvement in sarcoidosis is frequent. Our aim was to evaluate visual outcomes and treatment in a cohort of patients with ocular sarcoidosis. Retrospective study of 342 patients with sarcoidosis from 1999 to 2019 in a university hospital. Ocular manifestations and systemic treatments were assessed: glucocorticoids (GC), conventional synthetic immunosuppressive drugs (csIS) and biological therapy (BT). Best corrected visual acuity (BCVA) according to treatments was compared at diagnosis and after one-year follow-up. Ocular sarcoidosis was observed in 65 patients (19%). Uveitis was the most frequent manifestation (83%). GC was used in 52 (80%) patients, csIS in 32 (49.2%) and BT in 17 (26.2%). BT was most used in panuveitis (62.5%). Median BCVA at diagnosis and one year later was 0.6 and 0.9, respectively, no significant differences were observed. In conclusion severe manifestations require an aggressive treatment. In uveitis, a significant improvement in BCVA was observed after one year of follow-up.